725 filings
DEF 14A
APTO
Aptose Biosciences Inc
Definitive proxy
15 May 24
11:47am
10-Q
2024 Q1
APTO
Aptose Biosciences Inc
Quarterly report
14 May 24
5:06pm
8-K
APTO
Aptose Biosciences Inc
14 May 24
Aptose Reports Results for the First Quarter 2024
4:15pm
8-K
APTO
Aptose Biosciences Inc
6 May 24
Regulation FD Disclosure
4:45pm
8-K
APTO
Aptose Biosciences Inc
1 May 24
Entry into a Material Definitive Agreement
4:30pm
8-K
11qfo315ee976
26 Apr 24
Entry into a Material Definitive Agreement
7:30am
8-K
kuy plrmqstkwxfsd6
5 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:05pm
8-K
kx5dxf30jln jamw2t
26 Mar 24
Aptose Reports Results for the Fourth Quarter and Full Year 2023
4:04pm
8-K
fv6ybg
18 Mar 24
Regulation FD Disclosure
4:45pm
8-K
t8h 22fpyp3d
1 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
m4fwogcvaof2oj
31 Jan 24
Regulation FD Disclosure
4:02pm
8-K
k87v7cfapapr3
29 Jan 24
Entry into a Material Definitive Agreement
9:44pm
424B4
c2wv6sz
26 Jan 24
Prospectus supplement with pricing info
5:30pm
8-K
l2fno
26 Jan 24
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
8:00am
EFFECT
3jnw4yvqu
26 Jan 24
Notice of effectiveness
12:15am
S-1MEF
2pd ovc48
25 Jan 24
Registration of additional securities for an S-1
9:44pm
CORRESP
9qkh4d8jeqbeuc3wg
24 Jan 24
Correspondence with SEC
12:00am